KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amgen (AMGN) Research & Development (2016 - 2025)

Historic Research & Development for Amgen (AMGN) over the last 17 years, with Q3 2025 value amounting to $1.9 billion.

  • Amgen's Research & Development rose 3103.45% to $1.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 billion, marking a year-over-year increase of 1870.45%. This contributed to the annual value of $6.0 billion for FY2024, which is 2466.56% up from last year.
  • Per Amgen's latest filing, its Research & Development stood at $1.9 billion for Q3 2025, which was up 3103.45% from $1.7 billion recorded in Q2 2025.
  • Over the past 5 years, Amgen's Research & Development peaked at $1.9 billion during Q3 2025, and registered a low of $959.0 million during Q1 2022.
  • In the last 5 years, Amgen's Research & Development had a median value of $1.3 billion in 2024 and averaged $1.3 billion.
  • As far as peak fluctuations go, Amgen's Research & Development crashed by 2180.03% in 2022, and later skyrocketed by 3438.37% in 2024.
  • Amgen's Research & Development (Quarter) stood at $1.3 billion in 2021, then decreased by 1.78% to $1.3 billion in 2022, then rose by 15.86% to $1.5 billion in 2023, then grew by 12.39% to $1.7 billion in 2024, then increased by 10.21% to $1.9 billion in 2025.
  • Its Research & Development stands at $1.9 billion for Q3 2025, versus $1.7 billion for Q2 2025 and $1.5 billion for Q1 2025.